[Featured Stock] Celltrion Healthcare Surges Over 9% on Earnings Expectations
On the 12th, Celltrion Healthcare showed strong performance.
As of 10:32 AM on the same day, Celltrion Healthcare's stock price was trading at 73,200 KRW, up 9.42% compared to the previous trading day.
Celltrion Healthcare is expected to have recorded operating revenue of 61.8 billion KRW in the first quarter, an increase of about 37% compared to the same period last year.
Hot Picks Today
Dramatic Agreement Reached on Eve of Samsung Electronics General Strike... Minister Kim Young-hoon: "Showcased Korea's Strength in Dialogue" (Update)
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Jae-kyung Park, a researcher at Hana Securities, stated, "It is difficult to confirm an improvement in Celltrion Healthcare's profitability in 2023," but added, "Attention should be paid to events driving 2024 performance, such as the FDA approval of Uplima starting in the second quarter, the launch of Uplima in the U.S. in the second half of this year, and its listing on major PBM prescription formularies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
